Company news

CRISPR Therapeutics AG news in 2025

CRISPR Therapeutics AG's news releases, calls and decks from 2025, newest first.

View company

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

December 21, 2025

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

November 9, 2025

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

November 7, 2025

CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency Utilizing Novel SyNTase Editing Platform

October 13, 2025

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

October 9, 2025

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

September 30, 2025

CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

September 21, 2025

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

September 8, 2025

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2025

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 3, 2025

CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025

June 29, 2025

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

June 25, 2025

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

May 18, 2025

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 5, 2025

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025

CRISPR Therapeutics Announces Transition of Chief Operating Officer

March 25, 2025

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

February 25, 2025

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 10, 2025

CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

January 28, 2025

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

January 12, 2025

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

January 6, 2025

Decks in 2025